{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-021506","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.932645+00:00","generated_at":"2026-05-23T00:57:28.733220+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Foghorn Therapeutics appoints Neil Gallagher and Stuart Duty to Board of Directors","bullets":["Stuart Duty and Neil Gallagher appointed effective May 1, 2025 as Class II directors.","Each granted initial option to purchase 50,000 shares vesting over three years.","Duty to serve on Audit Committee; Gallagher on Science Committee.","Duty receives annual cash retainers $40,000 board + $7,500 audit; Gallagher $40,000 + $5,000 science.","Audit Committee now has three independent members, regaining Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-021506","json":"https://secwatch.observer/filing/0001628280-25-021506.json","markdown":"https://secwatch.observer/filing/0001628280-25-021506.md","text":"https://secwatch.observer/filing/0001628280-25-021506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/0001628280-25-021506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/fhtx-20250425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:57:28.733220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ccea0da50","claim":"Neil J. Gallagher was appointed as Director at Foghorn Therapeutics Inc..","evidence_excerpt":"appointed Neil J. Gallagher, M.D., Ph.D. to the Board, effective May 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/0001628280-25-021506-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d535e86da6","claim":"Stuart Duty was appointed as Director at Foghorn Therapeutics Inc..","evidence_excerpt":"appointed Stuart Duty to the Board, effective May 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/0001628280-25-021506-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}